000303016 001__ 303016
000303016 005__ 20250819093532.0
000303016 0247_ $$2doi$$a10.3205/000339
000303016 0247_ $$2pmid$$apmid:40655928
000303016 0247_ $$2pmc$$apmc:PMC12247573
000303016 037__ $$aDKFZ-2025-01463
000303016 041__ $$aEnglish
000303016 082__ $$a310
000303016 1001_ $$aDietz, Andreas$$b0
000303016 245__ $$aEvidence-based guideline diagnosis, treatment, prevention and aftercare of oropharyngeal and hypopharyngeal carcinoma. = GMS Ger Med Sci
000303016 260__ $$aBerlin$$bGerman Medical Science (GMS) gGmbH$$c2025
000303016 3367_ $$2DRIVER$$aarticle
000303016 3367_ $$2DataCite$$aOutput Types/Journal article
000303016 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1755588906_6401$$xReview Article
000303016 3367_ $$2BibTeX$$aARTICLE
000303016 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303016 3367_ $$00$$2EndNote$$aJournal Article
000303016 500__ $$a2025 Jun 24:23:Doc03
000303016 520__ $$aThe guideline is being drawn up as a joint guideline for oropharyngeal and hypopharyngeal carcinoma. Oropharyngeal carcinoma in particular has experienced the greatest increase in incidence among all head and neck carcinomas in the last 20 years and is now the sixth most common cancer in men in Germany. Together with hypopharyngeal carcinoma, these tumors are currently the most common cancer entity in the head and neck region. Due to the association with human papillomavirus type 16 (HPV16), we now distinguish two groups of oropharyngeal carcinomas in Germany: HPV16-positive (approx. 35%) and HPV-negative (approx. 65%). A HPV16 association with hypopharyngeal carcinoma has not been described. The therapy covers the entire spectrum of head and neck surgery, including diversified reconstructive procedures, transoral and external approaches, the options for primary and adjuvant radiotherapy (possibly in combination with chemotherapy) and the current recommendations for drug-based tumor therapy, which range from classic chemotherapy to immuno-oncology. In addition, measures for early detection and prevention are carried out, with particular consideration of the HPV16-associated genesis of oropharyngeal carcinoma, as well as adequate rehabilitation after the primary treatment of oropharyngeal and hypopharyngeal carcinomas. Finally, the treatment options for recurrences or distant metastases that cannot be cured in the further course of the disease are shown and classified.
000303016 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000303016 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000303016 650_7 $$2Other$$aHPV16
000303016 650_7 $$2Other$$ahead and neck cancer
000303016 650_7 $$2Other$$ahypopharynx carcinoma
000303016 650_7 $$2Other$$aoropahyrnx carcinoma
000303016 650_7 $$2Other$$ap16
000303016 650_2 $$2MeSH$$aHumans
000303016 650_2 $$2MeSH$$aMale
000303016 650_2 $$2MeSH$$aAftercare: standards
000303016 650_2 $$2MeSH$$aCombined Modality Therapy
000303016 650_2 $$2MeSH$$aEvidence-Based Medicine
000303016 650_2 $$2MeSH$$aGermany
000303016 650_2 $$2MeSH$$aHuman papillomavirus 16
000303016 650_2 $$2MeSH$$aHypopharyngeal Neoplasms: therapy
000303016 650_2 $$2MeSH$$aHypopharyngeal Neoplasms: diagnosis
000303016 650_2 $$2MeSH$$aHypopharyngeal Neoplasms: prevention & control
000303016 650_2 $$2MeSH$$aHypopharyngeal Neoplasms: virology
000303016 650_2 $$2MeSH$$aOropharyngeal Neoplasms: therapy
000303016 650_2 $$2MeSH$$aOropharyngeal Neoplasms: diagnosis
000303016 650_2 $$2MeSH$$aOropharyngeal Neoplasms: prevention & control
000303016 650_2 $$2MeSH$$aOropharyngeal Neoplasms: virology
000303016 650_2 $$2MeSH$$aPapillomavirus Infections: diagnosis
000303016 650_2 $$2MeSH$$aPapillomavirus Infections: therapy
000303016 7001_ $$aTaylor, Kathy$$b1
000303016 7001_ $$aBayer, Oliver$$b2
000303016 7001_ $$aSinger, Susanne$$b3
000303016 7001_ $$aFollmann, Markus$$b4
000303016 7001_ $$aNothacker, Monika$$b5
000303016 7001_ $$aLanger, Thomas$$b6
000303016 7001_ $$aKlussmann, Peter$$b7
000303016 7001_ $$aLang, Stephan$$b8
000303016 7001_ $$aHoffmann, Thomas$$b9
000303016 7001_ $$aMaschmeyer, Georg$$b10
000303016 7001_ $$aWiegand, Susanne$$b11
000303016 7001_ $$aFuchs, Michael$$b12
000303016 7001_ $$aWeichert, Wilko$$b13
000303016 7001_ $$0P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aHess, Jochen$$b14$$udkfz
000303016 7001_ $$aGuntinas-Lichius, Orlando$$b15
000303016 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b16$$udkfz
000303016 7001_ $$aLell, Michael$$b17
000303016 7001_ $$aBüntzel, Jens$$b18
000303016 7001_ $$aBalermpas, Panagiotis$$b19
000303016 7001_ $$aSchmidt, Kerstin$$b20
000303016 7001_ $$aSteingräber, Maria$$b21
000303016 7001_ $$aKlautke, Gunther$$b22
000303016 7001_ $$aHellmund, Herbert$$b23
000303016 7001_ $$aKissinger, Gunthard$$b24
000303016 7001_ $$aBrossart, Peter$$b25
000303016 7001_ $$aMaatouk, Imad$$b26
000303016 7001_ $$aLethaus, Bernd$$b27
000303016 7001_ $$aRaguse, Jan$$b28
000303016 7001_ $$aZöphel, Klaus$$b29
000303016 7001_ $$aLippach, Kristina$$b30
000303016 7001_ $$aSterr, Fritz$$b31
000303016 7001_ $$aChristiansen, Hans$$b32
000303016 7001_ $$aDuncker, Christian$$b33
000303016 7001_ $$aKeilmann, Annerose$$b34
000303016 7001_ $$aCici, Havva$$b35
000303016 7001_ $$aYzer, Jutta$$b36
000303016 7001_ $$aRelic, Alessandro$$b37
000303016 7001_ $$aParadies, Kerstin$$b38
000303016 7001_ $$aBudach, Wilfried$$b39
000303016 773__ $$0PERI:(DE-600)2113606-3$$a10.3205/000339$$gVol. 23$$pDoc03$$tGMS german medical science$$v23$$x1612-3174$$y2025
000303016 909CO $$ooai:inrepo02.dkfz.de:303016$$pVDB
000303016 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000303016 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000303016 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000303016 9141_ $$y2025
000303016 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000303016 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000303016 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-04-23T10:55:52Z
000303016 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-04-23T10:55:52Z
000303016 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2020-04-23T10:55:52Z
000303016 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-04-23T10:55:52Z
000303016 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-06
000303016 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-06
000303016 9201_ $$0I:(DE-He78)E220-20160331$$kE220$$lE220 Radioonkologie Radiobiologie$$x0
000303016 9201_ $$0I:(DE-He78)D320-20160331$$kD320$$lInfektionen und Krebs-Epidemiologie$$x1
000303016 980__ $$ajournal
000303016 980__ $$aVDB
000303016 980__ $$aI:(DE-He78)E220-20160331
000303016 980__ $$aI:(DE-He78)D320-20160331
000303016 980__ $$aUNRESTRICTED